<DOC>
	<DOCNO>NCT01673854</DOCNO>
	<brief_summary>The purpose study assess safety profile vemurafenib , 960 mg , administer 6 week , follow ipilimumab monotherapy patient BRAF V600 mutate advanced/metastatic melanoma .</brief_summary>
	<brief_title>Phase II Safety Study Vemurafenib Followed Ipilimumab Subjects With V600 BRAF Mutated Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Key Men woman 18 year age old Histologic diagnosis malignant melanoma test positive BRAF V600 mutation Previously untreated unresectable Stage III Stage IV melanoma Complete set brain/neck , chest , abdomen/pelvis axial radiograph take within 28 day first dose study drug Measurable melanoma physical radiographic examination Brain metastases stable radiation least 1 month corticosteroid therapy â‰¥30 day prior enrollment Eastern Cooperative Oncology Group performance status 0 1 Adequate hematologic parameter renal hepatic function Key Primary ocular melanoma Active brain metastasis symptoms require corticosteroid treatment Any malignancy patient diseasefree less 2 year , exception adequately treat cured basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix History current active autoimmune disease , include limited inflammatory bowel disease , rheumatoid arthritis , autoimmune thyroiditis , autoimmune hepatitis , systemic sclerosis , systemic lupus erythematosus , autoimmune vasculitis , autoimmune neuropathy History current immunodeficiency disease , splenectomy , splenic irradiation Prior anticancer therapy investigational product &lt; 4 week prior enrollment Prior therapy BRAF MEK inhibitor prior investigational anticancer immunotherapy ; Prior therapy immunosuppressive agent within past 2 year Concomitant therapy anticancer potent immunosuppressive agent , surgery , radiotherapy , investigational anticancer therapy , chronic use systemic corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>